Scoop: One of Phil Krause’s post-FDA gigs, a biotech try­ing to de­vel­op a Shin­grix com­peti­tor, goes up for sale

A small Ne­bras­ka biotech that was at­tempt­ing to de­vel­op a next-gen­er­a­tion shin­gles vac­cine, in a bid to im­prove up­on Glax­o­SmithK­line’s Shin­grix, is up for sale and let go of most em­ploy­ees in mid-Feb­ru­ary, End­points News has learned.

Ad­ju­vance Tech­nolo­gies — which re­cruit­ed for­mer FDA deputy vac­cines di­rec­tor Phil Krause as a con­sul­tant in Jan­u­ary — is “seek­ing a strate­gic merg­er or sale,” Pres­i­dent Melis­sa Mal­hame con­firmed to End­points in an email. Mal­hame de­clined to pro­vide fur­ther com­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER